Observing cardiovascular changes in patients with hypertension
Multi-center Study on New Cardiovascular Remodeling and Function Parameters in Hypertension
Qilu Hospital of Shandong University · NCT05638503
This study is testing how different types of high blood pressure affect heart health in 2,200 patients over four years to see if certain heart measurements can help predict future heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2200 (estimated) |
| Ages | 30 Years to 75 Years |
| Sex | All |
| Sponsor | Qilu Hospital of Shandong University (other) |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT05638503 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the relationship between various configurations of hypertension and the occurrence of cardiovascular events using different reference ranges. It will enroll 2,200 hypertensive patients across twenty research centers, with follow-ups at 12, 24, 36, and 48 months. Participants will undergo physical examinations, ECGs, laboratory tests, echocardiography, and carotid ultrasounds at baseline and during follow-ups. The study will analyze echocardiographic parameters to understand their correlation with cardiovascular events and prognosis in the hypertensive population.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 30-75 with hypertension, either untreated or on antihypertensive medication.
Not a fit: Patients with secondary hypertension or severe cardiovascular conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cardiovascular risks in hypertensive patients.
How similar studies have performed: Previous studies have indicated the significance of cardiac remodeling in hypertensive populations, suggesting potential for success in this observational approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 30-75 years old; 2. No antihypertensive drugs were used and three blood pressure measurements were conducted on different days, with systolic blood pressure ≥ 140 mmHg (1 mmHg=0.133 kPa) and/or diastolic blood pressure ≥ 90 mmHg; or have a history of hypertension and are using antihypertensive drugs, even if the blood pressure is lower than 140/90 mmHg; 3. Left ventricular ejection fraction was normal (LVEF ≥ 0.5). 4. All patients agreed to participate in the experiment and signed the informed consent form. Exclusion Criteria: 1. Secondary hypertension caused by renal parenchymal diseases, renal vascular diseases, coarctation of aorta and endocrine system diseases; 2. Severe cardiovascular and cerebrovascular diseases; heart valve disease; persistent atrial fibrillation and severe arrhythmia; previously undergone cardiovascular disease surgery; 3. Abnormal liver function; abnormal renal function and diabetes; 4. Pregnant or breastfeeding women; 5. Expected survival time due to non-cardiovascular disease\<4 years; 6. Patients with poor echocardiographic image quality.
Where this trial is running
Jinan, Shandong
- Qilu Hospital of Shandong University — Jinan, Shandong, China (RECRUITING)
Study contacts
- Principal investigator: Mei Zhang, PhD — Qilu Hospital of Shandong University
- Study coordinator: Mei Zhang, PhD
- Email: daixh@vip.sina.com
- Phone: +86-18560086629
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hypertension, Echocardiography, Cardiovascular remodeling